Memantine in patients with Alzheimer's disease receiving donepezil: New analyses of efficacy and safety for combination therapy

Alzheimer's Research and Therapy

Volumn 5, Issue 1, 2013, Pages

  Atri, Alireza ^a,b,c   Molinuevo, José L ^d   Lemming, Ole ^e   Wirth, Yvonne ^f   Pulte, Irena ^g   Wilkinson, David ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e H LUNDBECK A S   (Denmark)

^f Wirth Consulting   (Germany)

^g MERZ PHARMACEUTICALS GMBH   (Germany)

^h MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; COGNITION; CONFUSION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FALLING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84872399089     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt160     Document Type: Article

References (41)

1. Realistic expectations for treatment success in Alzheimer's disease. DS Geldmacher, L Frolich, RS Doody, T Erkinjuntti, B Vellas, RW Jones, S Banerjee, P Lin, M Sano, J Nutr Health Aging 2006 10 417 429 17066215
2. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. JL Cummings, Alzheimers Dement 2006 2 263 271 10.1016/j.jalz.2006.07.001 19595897
3. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. MF Folstein, SE Folstein, PR McHugh, J Psychiat Res 1975 12 189 198 10.1016/0022-3956(75)90026-6 1202204
4. Memantine in severe dementia: results of the M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). B Winblad, N Poritis, Int J Geriatr Psychiatry 1999 14 135 146 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0 10885864
5. Memantine in moderate-to-severe Alzheimer's disease. B Reisberg, R Doody, A Stöffler, F Schmitt, S Ferris, HJ Möbius, Memantine Study Group, N Engl J Med 2003 348 1333 1341 10.1056/NEJMoa013128 12672860
6. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. D Wilkinson, HF Andersen, Dement Geriatr Cogn Disord 2007 24 138 145 10.1159/000105162 17622761
7. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. SL Rogers, MR Farlow, RS Doody, R Mohs, LT Friedhoff, Neurology 1998 50 136 145 10.1212/WNL.50.1.136 9443470
8. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. H Feldman, S Gauthier, J Hecker, B Vellas, P Subbiah, E Whalen, Donepezil MSAD Study Investigators Group, Neurology 2001 57 613 620 10.1212/WNL.57.4.613 11524468
9. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. B Winblad, K Engedal, H Soininen, F Verhey, G Waldemar, A Wimo, AL Wetterholm, R Zhang, A Haglund, P Subbiah, Donepezil Nordic Study Group, Neurology 2001 57 489 495 10.1212/WNL.57.3.489 11502918
10. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. B Winblad, SE Black, A Homma, EM Schwam, M Moline, Y Xu, CA Perdomo, J Swartz, K Albert, Curr Med Res Opin 2009 25 2577 2587 19735164
11. Donepezil for dementia due to Alzheimer's disease. J Birks, RJ Harvey, Cochrane Database Syst Rev 2006 CD001190
12. Memantine for dementia. R McShane, A Areosa Sastre, N Minakaran, Cochrane Database Syst Rev 2006 CD003154
13. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. D Wilkinson, R Schindler, E Schwam, G Waldemar, RW Jones, S Gauthier, OL Lopez, J Cummings, Y Xu, HH Feldman, Dement Geriatr Cogn Disord 2009 28 244 251 10.1159/000241877 19786776
14. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. S Gauthier, JL Molinuevo, Alzheimers Dement 2012 published online 27 October 2012, doi:10.1016/j.jalz.2011.11.005
15. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. AP Periclou, D Ventura, T Sherman, N Rao, WT Abramowitz, Ann Pharmacother 2004 38 1389 1394 10.1345/aph.1D638 15266045
16. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. PN Tariot, MR Farlow, GT Grossberg, SM Graham, S McDonald, I Gergel, Memantine Study Group, JAMA 2004 291 317 324 10.1001/jama.291.3.317 14734594
17. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. AP Porsteinsson, GT Grossberg, J Mintzer, JT Olin, Memantine MEM-MD-12 Study Group, Curr Alzheimer Res 2008 5 83 89 10.2174/156720508783884576 18288936
18. J Saxton, KL McGonigle, AA Swihart, F Boller, The Severe Impairment Battery Bury St Edmunds: Thames Valley Test Company 1993
19. Severe impairment battery. A neuropsychological test for severely demented patients. M Panisset, M Roudier, J Saxton, F Boller, Arch Neurol 1994 51 41 45 10.1001/archneur.1994.00540130067012 8274108
20. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. FA Schmitt, W Ashford, C Ernesto, J Saxton, LS Schneider, CM Clark, SH Ferris, JA Mackell, K Schafer, LJ Thal, Alzheimer Dis Assoc Disord 1997 11 Suppl 2 51 56
21. A new rating scale for Alzheimer's disease. WG Rosen, RC Mohs, KL Davis, Am J Psychiatry 1984 141 1356 1364 6496779
22. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. D Galasko, D Bennett, M Sano, C Ernesto, R Thomas, M Grundman, S Ferris, Alzheimer Dis Assoc Disord 1997 11 Suppl 2 33 39 9305513
23. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. D Galasko, F Schmitt, R Thomas, S Jin, D Bennett, Alzheimer's Disease Cooperative Study, J Int Neuropsychol Soc 2005 11 446 453 16209425
24. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. B Reisberg, L Schneider, R Doody, R Anand, H Feldman, H Haraguchi, R Kumar, U Lucca, CA Mangone, E Mohr, JC Morris, S Rogers, T Sawada, Alzheimer Dis Assoc Disord 1997 11 Suppl 3 8 18 9194961
25. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. LS Schneider, JT Olin, RS Doody, CM Clark, JC Morris, B Reisberg, FA Schmitt, M Grundman, RG Thomas, SH Ferris, Alzheimer Dis Assoc Disord 1997 11 Suppl 2 22 32 9305510
26. J Cohen, Statistical Power Analysis for the Behavioral Sciences New York, NY: Psychology Press, Taylor & Francis Group Second 1988
27. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. K Rockwood, J Neurol Neurosurg Psychiatry 2004 75 677 685 10.1136/jnnp.2003.029074 15090558
28. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. FA Schmitt, CH van Dyck, CH Wichems, JT Olin, Memantine MEM-MD-02 Study Group, Alzheimer Dis Assoc Disord 2006 20 255 262 10.1097/01.wad.0000213860.35355.d4 17132970
29. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. HH Feldman, FA Schmitt, JT Olin, Alzheimer Dis Assoc Disord 2006 20 263 268 10.1097/01.wad.0000213859.35355.59 17132971
30. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. B Winblad, RW Jones, Y Wirth, A Stöffler, HJ Möbius, Dement Geriatr Cogn Disord 2007 24 20 27 10.1159/000102568 17496417
31. Meta-analysis of six-month memantine trials in Alzheimer's disease. RS Doody, PN Tariot, E Pfeiffer, JT Olin, SM Graham, Alzheimers Dement 2007 3 7 17 10.1016/j.jalz.2006.10.004 19595910
32. Long-term course and effectiveness of combination therapy in Alzheimer disease. A Atri, LW Shaughnessy, JJ Locascio, JH Growdon, Alzheimer Dis Assoc Disord 2008 22 209 221 10.1097/WAD.0b013e31816653bc 18580597
33. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. OL Lopez, JT Becker, AS Wahed, J Saxton, RA Sweet, DA Wolk, W Klunk, ST Dekosky, J Neurol Neurosurg Psychiatry 2009 80 600 607 10.1136/jnnp.2008.158964 19204022
34. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. A Atri, SD Rountree, OL Lopez, RS Doody, Neurodegener Dis 2012 10 170 174 10.1159/000335156 22327239
35. Donepezil and memantine for moderate-to-severe Alzheimer's disease. R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, A Burns, T Dening, D Findlay, C Holmes, A Hughes, R Jacoby, R Jones, R Jones, I McKeith, A Macharouthu, J O'Brien, P Passmore, B Sheehan, E Juszczak, C Katona, R Hills, M Knapp, C Ballard, R Brown, S Banerjee, C Onions, M Griffin, J Adams, R Gray, et al. N Engl J Med 2012 366 893 903 10.1056/NEJMoa1106668 22397651
36. Two drugs are not better than one for treating moderate to severe Alzheimer disease, British investigators report: why some US neurologists don't agree. G Shaw, Neurology Today 2012 12 12 13
37. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. SD Rountree, W Chan, VN Pavlik, EJ Darby, S Siddiqui, RS Doody, Alzheimers Res Ther 2009 1 7 10.1186/alzrt7 19845950
38. Long-term progression of Alzheimer's disease in patients under antidementia drugs. S Gillette-Guyonnet, S Andrieu, F Nourhashemi, V Gardette, N Coley, C Cantet, S Gauthier, PJ Ousset, B Vellas, REAL.FR study group, Alzheimers Dement 2011 7 579 592 10.1016/j.jalz.2011.02.009 22055975
39. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. GK Wilcock, CG Ballard, JA Cooper, H Loft, J Clin Psychiatry 2008 69 341 348 10.4088/JCP.v69n0302 18294023
40. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). JT Olin, V Bhatnagar, P Reyes, B Koumaras, X Meng, S Brannan, Int J Geriatr Psychiatry 2010 25 419 426 10.1002/gps.2355 19670390
41. Combination therapy for Alzheimer's disease. L Patel, GT Grossberg, Drugs Aging 2011 28 539 546 10.2165/11591860-000000000-00000 21721598